Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Feb 7:14:72.
doi: 10.1186/1471-2407-14-72.

Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression

Juliana Passos Paschoal, Vagner Bernardo, Nathalie Henriques Silva Canedo, Osmar Damasceno Ribeiro, Adriana Caroli-Bottino, Vera Lucia Pannain  1
Affiliations
Comparative Study

Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression

Juliana Passos Paschoal et al. BMC Cancer. .

Abstract

Background: Angiogenesis is a proliferative process resulting in the development of new blood vessels from existing endothelial cells and is considered crucial for tumor growth and metastasis. Tumor angiogenesis can be quantified by microvascular density (MVD), which is evaluated in highly vascularized tumor areas (hot spots) by immunohistochemical assays using CD34 and CD31 pan-endothelial antibodies. More recently, CD105 has been successfully used for some tumor types because it could discriminate neovascularization. The expression of CD34 and CD105 in hepatocellular carcinomas (HCC) and hepatic precancerous lesions has been reported-although the results for CD105 are controversial-but to the best our knowledge, CD105 has not been previously investigated in dysplastic nodules (DN). We investigated and compared MVD-CD34 and MVD-CD105 immunoexpression in tissues containing different stages of hepatocarcinogenesis, including DN.

Methods: A total of 31 regenerative nodules (RN), 26 DN and 25 small HCC from explants were used for immunohistochemical tests with CD34 and CD105 antibodies. Antibody expression was quantified by computerized image analysis measurement of MVD, areas containing highly positive endothelial cells within the nodules.

Results: The median MVD for CD34 was higher in HCC than in DN and RN (p < 0.01), and was higher in DN compared with RN (p = 0.033). In contrast, MVD with CD105 was higher in RN, and the difference was significant in RN and DN compared with HCC (p = 0.019 and p = 0.012, respectively). When MVD with CD34 and CD105 were compared within a single group, there was a significant predominance of CD105 in RN and DN (p < 0.01). In addition, MVD-C34 in HCC predominated compared with MVD-CD105, but the difference was not statistically significant (p = 0.128).

Conclusions: This study identified a close relationship between CD105 and liver cirrhosis, and that CD34 antibody is a good endothelial marker for hepatic carcinogenesis. There was no difference between the use of CD105 and CD34 antibodies in preneoplastic lesions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MVD expression ratio for CD105 antibody according to diagnostic group. Y axis represents MVD for each group. RN = regenerative nodules; ND = dysplastic nodules; HCC = hepatocellular carcinoma.
Figure 2
Figure 2
MVD expression ratio for CD34 antibody according to diagnostic group. Y axis represents MVD for each group. RN = regenerative nodules; ND = dysplastic nodules; HCC = hepatocellular carcinoma.
Figure 3
Figure 3
CD105 immunoexpression in sinusoidal cells of RN (hot spot area). Original magnification, x400.
Figure 4
Figure 4
CD105 immunoexpression in microvessels of HCC (hot spot area). Original magnification, x400.
Figure 5
Figure 5
CD34 immunoexpression in sinusoidal cells of RN (hot spot area). Original magnification, x400.
Figure 6
Figure 6
CD34 immunoexpression in microvessels of HCC (hot spot area). Original magnification, x400.
See this image and copyright information in PMC

References

    1. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 1977;15:53–65. - PubMed
    1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186. doi: 10.1056/NEJM197111182852108. - DOI - PubMed
    1. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 2001;7:1194–1201. doi: 10.1038/nm1101-1194. - DOI - PubMed
    1. Ozalp S, Yalcin OT, Oner U, Tanir HM, Acikalin M, Sarac I. Microvasculardensity as a prognostic factor in preinvasive and invasive cervical lesions. Eur J Gynaecol Oncol. 2003;24:425–428. - PubMed
    1. Fisseler-Eckhoff A, Rothstein D, Müller KM. Neovascularization in hyperplastic, metaplastic and potentially preneoplastic lesions of the bronchial mucosa. Virchows Arch. 1996;429:95–100. - PubMed

Publication types

MeSH terms